Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-017-0562-8
Abstract: BackgroundIn hemodialysis (HD), switching from erythropoiesis-stimulating agent (ESA) originators to biosimilars is associated with the need for doses approximately 10% higher, according to industry-driven studies.ObjectiveThe aim of this study was to evaluate the efficacy on… read more here.
Keywords: esa originators; control; switch; study ... See more keywords
Extremely Low Dose of Erythropoiesis-Stimulating Agent May be Associated with Increased Mortality in Hemodialysis Patients.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of nephrology"
DOI: 10.1159/000529806
Abstract: INTRODUCTION Although high dose erythropoiesis-stimulating agent (ESA) has been shown to increase mortality risk and adverse cardiovascular events in hemodialysis patients, the safety of extremely low dose ESA is unclear. METHODS We retrospectively analyzed the… read more here.
Keywords: extremely low; mortality; hemodialysis patients; esa dose ... See more keywords
Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
Sign Up to like & getrecommendations! Published in 2017 at "PLoS ONE"
DOI: 10.1371/journal.pone.0172735
Abstract: The increased risks of death and adverse events with erythropoiesis-stimulating agent (ESA) therapy targeting a higher hemoglobin level are established. It is uncertain whether the adverse effects of ESA therapy are related to dose and… read more here.
Keywords: trial; erythropoiesis stimulating; fixed low; hemodialysis patients ... See more keywords